Abstract
BackgroundBiological disease-modifying anti-rheumatic drugs (bioDMARDs) are generally used in combination with conventional synthetic DMARDs (csDMARDs) in the treatment of rheumatoid arthritis (RA). Anti-TNF agents are more effective in combination with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have